Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials
2023; Oxford University Press; Volume: 230; Issue: 1 Linguagem: Inglês
10.1093/infdis/jiad580
ISSN1537-6613
AutoresEmilie R Elliot, Joseph W. Polli, Parul Patel, Louise Garside, Richard Grove, Vincent A. Barnett, Jeremy Roberts, Sri Byrapuneni, Herta Crauwels, Susan L. Ford, Rodica Van Solingen‐Ristea, Eileen Birmingham, Ronald D’Amico, Bryan Baugh, Jean van Wyk,
Tópico(s)Chronic Lymphocytic Leukemia Research
ResumoCabotegravir + rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of HIV-1 virologic suppression. This post hoc analysis summarizes CAB + RPV LA results by baseline body mass index (BMI) category among Phase 3/3b trial participants.
Referência(s)